{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:53:15Z","timestamp":1759513995075,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005247","name":"University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13643-019-1047-z","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T15:18:21Z","timestamp":1560266301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses"],"prefix":"10.1186","volume":"8","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Camateros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"issue":"1","key":"1047_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang J, Shalabi A, Vm H-L. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84\u201391.","journal-title":"Ann Oncol"},{"issue":"2","key":"1047_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"23","key":"1047_CR3","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.2009.23.1183","volume":"27","author":"NJ Meropol","year":"2009","unstructured":"Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, et al. American society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868\u201374.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1047_CR4","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jtho.2016.05.032","volume":"11","author":"K Matter-Walstra","year":"2016","unstructured":"Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous nsclc including pd-l1 testing. J Thorac Oncol. 2016;11(11):1846\u201355.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1047_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1080\/13696998.2016.1184155","volume":"19","author":"K Vouk","year":"2016","unstructured":"Vouk K, Benter U, Amonkar MM, Marocco A, Stapelkamp C, Pfersch S, et al. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 2016;19(9):900\u201312.","journal-title":"J Med Econ"},{"key":"1047_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","volume":"48","author":"F Tartari","year":"2016","unstructured":"Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. Economic sustainability of anti-pd-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20\u20134.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"1047_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.socscimed.2005.10.023","volume":"62","author":"A Gafni","year":"2006","unstructured":"Gafni A, Birch S. Incremental cost-effectiveness ratios (icers): the silence of the lambda. Soc Sci Med. 2006;62(9):2091\u2013100.","journal-title":"Soc Sci Med"},{"issue":"29","key":"1047_CR8","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1200\/JCO.2014.57.8740","volume":"32","author":"N Khera","year":"2014","unstructured":"Khera N. Reporting and grading financial toxicity. J Clin Oncol. 2014;32(29):3337\u20138.","journal-title":"J Clin Oncol"},{"key":"1047_CR9","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (cheers) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"},{"issue":"2","key":"1047_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (cheers)--explanation and elaboration: a report of the ispor health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"6","key":"1047_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1586\/14737167.2015.1087316","volume":"15","author":"M Meregaglia","year":"2015","unstructured":"Meregaglia M, Cairns J. Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):913\u201329.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1047_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13561-017-0173-3","volume":"7","author":"K Edwards","year":"2017","unstructured":"Edwards K, Jones N, Newton J, Foster C, Judge A, Jackson K, et al. The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature. Health Econ Rev. 2017;7(1):37.","journal-title":"Health Econ Rev"},{"issue":"2","key":"1047_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40273-017-0577-2","volume":"36","author":"S Iannazzo","year":"2018","unstructured":"Iannazzo S, Iliza AC, Perrault L. Disease-modifying therapies for multiple sclerosis: a systematic literature review of cost-effectiveness studies. Pharmacoeconomics. 2018;36(2):189\u2013204.","journal-title":"Pharmacoeconomics"},{"key":"1047_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vhri.2018.05.003","volume":"16","author":"A Al Kadour","year":"2018","unstructured":"Al Kadour A, Wa M, Al-Badriyeh D. Pharmacoeconomics evaluations of oral anticancer agents: systematic review of characteristics, methodological trends, and reporting quality. Value Health Reg Issues. 2018;16:46\u201360.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"1047_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/jcpt.12384","volume":"41","author":"PM Aguiar","year":"2016","unstructured":"Aguiar PM, Lima TM, Storpirtis S. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality? J Clin Pharm Ther. 2016;41(2):189\u201397.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1047_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.radonc.2017.08.034","volume":"125","author":"C Monten","year":"2017","unstructured":"Monten C, Veldeman L, Verhaeghe N, Lievens Y. A systematic review of health economic evaluation in adjuvant breast radiotherapy: quality counted by numbers. Radiother oncol. 2017;125(2):186\u201392.","journal-title":"Radiother oncol"},{"key":"1047_CR17","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"issue":"1","key":"1047_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. Syst Rev. 2015;4(1):1.","journal-title":"Syst Rev"},{"key":"1047_CR19","unstructured":"Thomas J, Brunton J, Graziosi S. Eppi-reviewer 4.0: software for research synthesis. London: Social science research unit, Institute of education, University of london; 2010. Available from: \n                    https:\/\/eppi.ioe.ac.uk\/cms\/default.aspx?tabid=1913\n                    \n                  . Accessed 31 May 2019."},{"issue":"10","key":"1047_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1047_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, JPA I, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-1047-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-1047-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:32:37Z","timestamp":1591745557000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-1047-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-1047-z","relation":{},"ISSN":["2046-4053"],"issn-type":[{"type":"electronic","value":"2046-4053"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"24 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}